Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B

Background: Subcortical vascular dementia (SVaD) is considered the most common type of vascular dementia and often follows a slowly progressive course, simulating Alzheimer disease (AD). Whether the progressive cognitive decline is associated with pure SVaD or concomitant AD remains unknown. The purpose of this study was to determine what proportion of patients with SVaD lack abnormal amyloid imaging, and to examine differences in the clinical or MRI features between subjects with SVaD with cortical amyloid deposition and those without. Methods: We measured brain amyloid deposition using 11C-Pittsburgh compound B (PiB) PET in 45 patients (men: women = 19:26; mean age 74.2 ± 7.6 years) with SVaD. They all met DSM-IV criteria for vascular dementia and had severe white matter high signal intensities without territorial infarction or macrohemorrhage on MRI. Results: Thirty-one (68.9%) of 45 patients with SVaD were negative for cortical PiB binding. There was significant difference between 11C-PiB-positive and 11C-PiB-negative groups in terms of age (79.5 vs 71.9 years), Mini-Mental State Examination score (18.6 vs 22.6), the number of lacunes (3.9 vs 9.0), and the visual rating scale of hippocampal atrophy (3.1 vs 2.3). The neuropsychological assessments revealed that patients with 11C-PiB-negative SVaD performed better on the delayed recall of both the verbal and visual memory test than did those with 11C-PiB-positive scan. Conclusion: SVaD without abnormal amyloid imaging was more common than expected. Patients with SVaD with and without abnormal amyloid imaging differed in clinical and MRI features, although there was considerable overlap.

[1]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[3]  Brian J Bacskai,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[4]  Jong-Min Lee,et al.  Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment , 2007, NeuroImage.

[5]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[6]  D. Na,et al.  Pyramidal and extrapyramidal scale (PEPS): A new scale for the assessment of motor impairment in vascular cognitive impairment associated with small vessel disease , 2011, Clinical Neurology and Neurosurgery.

[7]  A. Korczyn Mixed Dementia—the Most Common Cause of Dementia , 2002, Annals of the New York Academy of Sciences.

[8]  P. Scheltens,et al.  Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.

[9]  C. Lyketsos,et al.  Classification of vascular dementia in the Cardiovascular Health Study Cognition Study , 2005, Neurology.

[10]  S. D. Preston,et al.  Cerebrovascular Disease Is a Major Factor in the Failure of Elimination of Aβ from the Aging Human Brain , 2002 .

[11]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[12]  Norbert Schuff,et al.  Neuropathological basis of magnetic resonance images in aging and dementia , 2008, Annals of neurology.

[13]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[14]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[15]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[16]  H. Chui,et al.  Subcortical ischaemic vascular dementia , 2002, The Lancet Neurology.

[17]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[18]  R. Kelley,et al.  Subcortical ischemic cerebrovascular dementia. , 2009, International review of neurobiology.

[19]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[20]  W. M. van der Flier,et al.  The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia , 2007, Stroke.

[21]  S. D. Preston,et al.  Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. , 2002, Annals of the New York Academy of Sciences.

[22]  W. Klunk,et al.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.

[23]  K. Nagata,et al.  Clinical diagnosis of vascular dementia , 2007, Journal of the Neurological Sciences.

[24]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[25]  James T. Becker,et al.  Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B , 2008, Journal of Neuroscience Methods.

[26]  H. Chui,et al.  Subcortical ischemic vascular dementia. , 2007, Neurologic clinics.